Data / Form D filings / Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc.: Form D filings
Lycia Therapeutics, Inc., a biotechnology company in South San Francisco, CA, filed 4 Form D notices with the SEC between 2020 and 2026. The latest, on June 25, 2026, reports $75 million sold of a $75 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 400 EAST JAMIE COURT, SUITE 200, South San Francisco, CA, 94080
- Phone
- (650) 392-3357
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1806540
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | New notice | $75,000,000 | $75,000,000 | 16 | Jun 10, 2026 | sec.gov | |
| May 23, 2024 | New notice | $106,600,004 | $106,600,004 | 16 | Apr 26, 2024 | sec.gov | |
| Sep 16, 2021 | New notice | $70,055,062 | $70,055,062 | 11 | Sep 2, 2021 | sec.gov | |
| Mar 17, 2020 | New notice | $50,390,410 | $25,390,410 | $25,000,000 | 1 | Mar 3, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| William Rieflin | Director | |
| Clare Ozawa | Director | |
| Ming Fang | Director | |
| Laurent Fischer | Director | |
| Tim Anderson | Director | |
| Aetna Wun Trombley | Executive Officer, Director | |
| Amy Bachrodt | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jun 22, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Lycia Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.